Has Jessica Khoury received payments from drug or device companies?

Yes. Drug and device makers reported $5,150 in general payments to Jessica Khoury across 80 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Jessica Khoury did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Jessica Khoury come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Jessica Khoury

Endocrinology, Diabetes & Metabolism · Saint Charles, MDNPI 1265042733

Payments from drug & device makers

$5,150in general payments, 2019–2025

Across 80 payments — averaging $64.37 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Johnson & Johnson$1K
AstraZeneca$607
E.r. Squibb & Sons, L.L.C.$530
Sanofi-aventis U.S. LLC$444
Gilead$326
GSK$223
plus $2K from 22 others

What the payments were for

Food & beverage$5,150100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Johnson & Johnson(2 entities)	18	$1,092
AstraZeneca(2 entities)	11	$607
E.r. Squibb & Sons, L.L.C.	5	$530
Sanofi-aventis U.S. LLC	6	$444
Gilead	3	$326
GSK	2	$223
ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)	3	$207
Dexcom, Inc.	3	$202
Amgen	1	$149
AbbVie	2	$145
Takeda Pharmaceuticals U.S.A., Inc.	2	$128
Beigene USA, Inc.	1	$125
Bristol Myers Squibb	1	$125
Eisai Inc.	1	$120
Lilly USA, LLC	5	$116
Mirati Therapeutics, Inc.	1	$112
Bayer	1	$108
Madrigal Pharmaceuticals	2	$61
Echosens North America, Inc.	1	$53
Tandem Diabetes Care, Inc.	1	$51
Novo Nordisk	2	$48
Corcept Therapeutics	2	$47
Insulet Corporation	1	$34
Xeris Pharmaceuticals, Inc.	1	$23
Novartis	1	$22
Recordati_rare_diseases_inc.	1	$18
Sequel Med Tech, LLC	1	$16
Cequr Corporation	1	$16

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,150 in reported general payments places this provider in the 70th percentile of 235 endocrinology, diabetes & metabolism providers in Maryland.

See all endocrinology, diabetes & metabolism providers in Maryland →

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Levothyroxine Sodium	15	$909

Paid to pharmacies, not to this prescriber.

Other endocrinology, diabetes & metabolism in Saint Charles

Jean ParkBaltimore$3.7M
Michael DempseyRockville$2.7M
Ilias SpanakisBaltimore$2.6M
Helena RodbardRockville$2.4M
Daniel GozziSuitland$1.2M
Martin SarkarFrederick$1.1M
Romeu AzevedoCamp Springs$1.1M
Nicholas ArgentoLaurel$1.1M
Philip LevinBaltimore$702K
David BrownRockville$497K

See the full list for Maryland →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →